Galmed Pharmaceuticals (NASDAQ: GLMD) terminates Yissum license agreement

Rhea-AI Filing Summary

Galmed Pharmaceuticals Ltd., through its wholly owned subsidiary Galmed Research and Development Ltd., and Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. entered into a mutual termination letter to end their 2021 License Agreement, effective July 31, 2026.

Upon termination, all rights to the licensed technology revert to Yissum, the subsidiary’s obligation to fund ongoing patent expenses ceases as of July 31, 2026, and Galmed will discontinue all activities related to the licensed technology. The company took this step to consolidate operations, reduce costs, and focus resources on commercialization of Colospan and continued development of Aramchol.

Key Figures

License termination effective date: July 31, 2026 Termination Letter date: July 28, 2026 Notice of termination date: July 21, 2026 +1 more

4 metrics

License termination effective date July 31, 2026 Effective date when the License Agreement with Yissum ends

Termination Letter date July 28, 2026 Date Galmed’s subsidiary and Yissum entered into the mutual termination letter

Notice of termination date July 21, 2026 Date the subsidiary notified Yissum of its decision to terminate the License Agreement

Form S-8 registration statements referenced 4 Number of Form S-8 Registration Statements into which this report is incorporated by reference

Key Terms

mutual termination letter, License Agreement, foreign private issuer, Registration Statements on Form F-3

4 terms

mutual termination letter regulatory

"entered into a mutual termination letter (the “Termination Letter”)"

License Agreement regulatory

"agreed to terminate the License Agreement, dated June 28, 2021"

A license agreement is a contract where the owner of intellectual property, technology, a brand, or other rights gives another party permission to use those assets under specified conditions, usually for fees, royalties or other payments. For investors it matters because such deals create or limit predictable revenue streams, affect profit margins, transfer legal and commercial risk, and can determine how quickly a company can grow — like renting out a patented tool to earn steady income while keeping ownership.

foreign private issuer regulatory

"Report of Foreign Private Issuer Pursuant to Rule 13a-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

Registration Statements on Form F-3 regulatory

"the Company’s Registration Statements on Form F-3 (Registration Nos."

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 07/29/2026 - 04:05 PM Accepted by SEC EDGAR 07/29/2026 - 04:05 PM Learn about SEC filing dates

FAQ

What did Galmed Pharmaceuticals (GLMD) change regarding its Yissum license?

Galmed Pharmaceuticals (GLMD) agreed to terminate its License Agreement with Yissum effective July 31, 2026. All rights to the licensed technology will revert to Yissum, and Galmed will stop funding related patent expenses and discontinue all activities involving that technology.

When does the Galmed (GLMD) and Yissum License Agreement officially end?

The License Agreement between Galmed (GLMD) and Yissum ends effective July 31, 2026. This follows Galmed’s notice of termination delivered on July 21, 2026 and a mutual termination letter signed on July 28, 2026 confirming the effective date.

How does the license termination affect Galmed Pharmaceuticals (GLMD) obligations?

After July 31, 2026, Galmed’s subsidiary will no longer fund ongoing patent expenses for the licensed patents. Galmed will also discontinue all activities related to the licensed technology, while all associated rights and technology revert fully to Yissum.

Why is Galmed Pharmaceuticals (GLMD) terminating the Yissum License Agreement?

Galmed Pharmaceuticals (GLMD) elected to terminate the Yissum License Agreement to consolidate operations and reduce costs. The company states it is refocusing its resources on commercialization of Colospan and the continued development of its drug candidate Aramchol.

What strategic programs is Galmed (GLMD) prioritizing after ending the Yissum license?

Following the license termination, Galmed (GLMD) is concentrating its resources on Colospan commercialization and the continued development of Aramchol. The company links this portfolio focus to broader efforts to streamline operations and manage its cost structure.

How is this Galmed (GLMD) license termination linked to its U.S. registration statements?

The report describing Galmed’s (GLMD) termination of the Yissum License Agreement is incorporated by reference into Form S-8 and Form F-3 registration statements, meaning those U.S. registrations now formally include this updated information about the company’s licensing portfolio.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of July 2026

001-36345

(Commission File Number)

GALMED PHARMACEUTICALS LTD.

(Exact name of Registrant as specified in its charter)

c/o Meitar Law Offices Abba Hillel Silver Rd.,

Ramat Gan, 5250608

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On July 28, 2026, Galmed Research and Development Ltd. (the “Subsidiary”), a wholly owned subsidiary of Galmed Pharmaceuticals Ltd. (the “Company”), and Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (“Yissum”) entered into a mutual termination letter (the “Termination Letter”), pursuant to which the parties agreed to terminate the License Agreement, dated June 28, 2021, as amended on August 31, 2021 and December 15, 2021 (the “License Agreement”), effective July 31, 2026. The Termination Letter was entered into following the Subsidiary’s delivery of notice to Yissum on July 21, 2026 of its decision to terminate the License Agreement and discontinue funding the licensed patents thereunder effective July 31, 2026.

As a result of the termination, all rights to the licensed technology will revert to Yissum, the Subsidiary’s obligation to fund ongoing patent expenses relating to the licensed patents will cease effective July 31, 2026, and the Company will discontinue all activities relating to the licensed technology.

The Company elected to terminate the License Agreement as part of its efforts to consolidate operations, reduce costs and focus its resources on the commercialization of Colospan and the continued development of Aramchol.

This Form 6-K is hereby incorporated by reference into the Company’s Registration Statements on Form S-8 (Registration Nos. 333-206292, 333-227441, 333-284163, and 333-290399) and the Company’s Registration Statements on Form F-3 (Registration Nos. 333-272722 and 333-283241).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Galmed Pharmaceuticals Ltd.
Date: July 29, 2026	By:	/s/ Allen Baharaff
		Allen Baharaff
		President and Chief Executive Officer